title: Evaluation of a dual chamber implantable cardioverter defibrillator for the treatment of atrial and ventricular arrhythmias.
abstract: Eighty-nine patients with a documented history of atrial tachyarrhythmias or fibrillation (AF) received a cardioverter defibrillator designed to selectively differentiate and treat atrial and ventricular arrhythmias. Twenty-two patients received a coronary sinus lead and, therefore, could use a separate shock vector for selective treatment of atrial tachyarrhythmias/AF. The device is designed to treat tachyarrhythmias with antitachycardia pacing (ATP) and/or shock therapy using an atrial and/or a ventricular shock vector. Patients underwent induction and shock termination of atrial or dual tachyarrhythmias (AF/VF) to verify proper device function and to measure the arrhythmia detection time with enhancements and preventive algorithms programmed On and Off, respectively. Detection time for 329 VF inductions was 2.41 +/- 0.64 seconds with enhancements On and 2.29 +/- 0.47 with enhancements Off (NS). At implant or predischarge, 283 AF and/or AF/VF (121 atrial and 162 atrial/ventricular fibrillation) were induced. Shock conversion efficacy was 89.8% with AF conversion energies ranging from 0.9 to 27 J. Thirteen of the 23 patients had atrial shock conversions using the separate shock vector with an average conversion energy of 1.9 +/- 1.4 J. (range 0.5-5 J). During follow-up the efficacy of ATP on atrial tachyarrhythmias was 59% and the efficacy of delivered shocks on AF was 85%. This new dual chamber cardioverter defibrillator appropriately detected and classified atrial arrhythmias, and shock therapy for AF was highly effective. The detection algorithm differentiated atrial tachyarrhythmia/AF and did not delay VF detection. The separate shock vector converted induced AF with energies ranging from 0.6 to 5 J.
authors.affiliation: Institute of Cardiology, University of Bologna, Policlinico S. Orsola-Via Massarenti 9, 40138 Bologna, Italy. cardio1@almadns.unibo.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Boriani
authors.forename: Christian
authors.initials: C
authors.lastname: Wollmann
authors.forename: Mauro
authors.initials: M
authors.lastname: Biffi
authors.forename: Martin
authors.initials: M
authors.lastname: Kühl
authors.forename: Andreas
authors.initials: A
authors.lastname: Schuchert
authors.forename: Johannes
authors.initials: J
authors.lastname: Sperzel
authors.forename: Sascha
authors.initials: S
authors.lastname: Stiller
authors.forename: Gianni
authors.initials: G
authors.lastname: Gasparini
authors.forename: Dirk
authors.initials: D
authors.lastname: Böcker
mesh_terms: D001281:Atrial Fibrillation / Q000503:physiopathology / Q000628:therapy*; D018592:Cross-Over Studies; D017147:Defibrillators, Implantable; D005260:Female; D006325:Heart Atria; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013610:Tachycardia / Q000503:physiopathology / Q000628:therapy*; D017180:Tachycardia, Ventricular / Q000628:therapy*